



## Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences

April 30, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 30, 2019-- [Tetraphase Pharmaceuticals, Inc.](#) (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that senior management will be participating at the SunTrust Robinson Humphrey 5<sup>th</sup> Annual Life Sciences Summit on Tuesday, May 7, 2019 at the Lotte New York Palace Hotel in New York City. Guy Macdonald, President and Chief Executive Officer of Tetraphase, will also present a corporate overview at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 1:30 p.m. ET at the Grant Hyatt Hotel in New York City.

A live audio webcast of the UBS Global Healthcare Conference presentation will be available on the Company's website at <https://tphase.gcs-web.com/events-presentations>. The archived presentation will be available for 30 days.

### **About Tetraphase Pharmaceuticals, Inc.**

Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA<sup>TM</sup> is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company's pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical trials, and TP-2846, which is in preclinical testing for acute myeloid leukemia. Please visit [www.tphase.com](http://www.tphase.com) for more company information.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190430005033/en/>

Source: Tetraphase Pharmaceuticals, Inc.

### **Media and Investor Contact:**

Jennifer Viera  
[jviera@tphase.com](mailto:jviera@tphase.com)  
617-600-7040